Comparison of pre-treatment and in-vivo dosimetry for advanced radiotherapy of prostate cancer

Agnieszka Bartnikowska; Grzegorz Cieślik; Mateusz Młodzik; Miguel Garcia-Argibay

doi:10.5603/RPOR.a2022.0027

Comparison of pre-treatment and in-vivo dosimetry for advanced radiotherapy of prostate cancer

Rep Pract Oncol Radiother. 2022 May 19;27(2):189-197. doi: 10.5603/RPOR.a2022.0027. eCollection 2022.

Authors

Agnieszka Bartnikowska^{1

2}, Grzegorz Cieślik¹, Mateusz Młodzik¹, Miguel Garcia-Argibay³

Affiliations

¹ Radiotherapy Department, Oncology Center, Opole, Poland.
² Institute of Physics, Opole University, Opole, Poland.
³ School of Medical Sciences, Örebro Universitet, Örebro, Sweden.

Abstract

Background: The usage of advanced radiotherapy techniques requires validation of a previously calculated dose with the precise delivery with a linear accelerator. This study aimed to review and evaluate new verification methods of dose distribution. Moreover, our purpose was to define an internal protocol of acceptance for in-vivo measurements of dose distribution.

Materials and methods: This study included 43 treatment plans of prostate cancer calculated using the Monte Carlo algorithm. All plans were delivered using the Volumetric Modulated Arc Therapy (VMAT) technique of advanced radiotherapy by the linear accelerator Elekta VersaHD. The dose distribution was verified using: MatriXX, iViewDose, and in-vivo measurements. The verification also included recalculation of fluence maps of quality assurance plans in another independent algorithm.

Results: The acceptance criterion of 95% points of dose in agreement was found for pre-treatment verification using MatriXX; the average γ value was 99.09 ± 0.93 (SD) and 99.64 ± 0.35 (SD) for recalculation in the Collapse Cone algorithm. Moreover, using the second algorithm in the verification process showed a positive correlation ρ = 0.58, p < 0.001. However, verification using iViewDose in a phantom and in-vivo did not meet this γ-pass rate.

Conclusions: Evaluation of gamma values for in-vivo measurements utilizing iViewDose software was helpful to establish an internal dosimetry protocol for prostate cancer treatments. We assumed value at a minimum of 50% points of the dose in agreement with the 3%/3 mm criterion as an acceptable compliance level. The recalculated dose distribution of QA plans in regard to the Collapse Cone algorithm in the other treatment planning system can be used as a pre-treatment verification method used by a medical physicist in their daily work. The effectiveness of use in iViewDose software, as a pre-treatment tool, is still debatable, unlike the MatriXX device.

Keywords: dosimetry; in-vivo dosimetry; prostate cancer; quality assurance.